Lee Una J, MacDiarmid Scott, Matthews Catherine A, Gillespie Emily, Peters Kenneth M
Virginia Mason Medical Center, 1100 Ninth Ave C7-URO, Seattle, WA, 98101, USA.
Alliance Urology Specialists, Greensboro, NC, USA.
Adv Ther. 2024 Jul;41(7):2635-2654. doi: 10.1007/s12325-024-02864-3. Epub 2024 May 15.
The tibial nerve is an established target for neuromodulation in the management of overactive bladder (OAB) and its associated symptoms, including urge urinary incontinence (UUI). Technologies are currently available to deliver tibial nerve stimulation (TNS) through percutaneous devices or through implantable devices. The benefits and safety of percutaneous TNS have led to it as a guideline-recommended therapy. However, patient compliance is limited by the burden of weekly office visits and the need for maintenance treatments. Further, insurance often only covers a limited number of lifetime visits for percutaneous TNS. These factors and others have led to the development, study, and utilization of implantable TNS devices. Implantable TNS devices deliver the same therapeutic mechanism of action for nerve stimulation with a permanent implanted device that provides at-home stimulation rather than in-office therapy delivery. Additionally, there is an added potential for dynamic and patient-centered stimulation. There is a large body of high-quality evidence published for TNS, including numerous randomized controlled trials published on percutaneous TNS which have consistently demonstrated superior efficacy to sham and similar efficacy to that of anticholinergic medications. Percutaneous TNS also performs better than conservative therapy including pelvic floor muscle training. The percutaneous and implantable approaches deliver nerve stimulation to the same target nerve, using the same mechanism of action. Therefore, data from randomized trials of percutaneous TNS are informative for implantable TNS devices. At the time of this article's publication, at least two implantable TNS devices have received marketing authorization from the Food and Drug Administration (FDA). The objective of this review is to discuss the mechanism of action for TNS and summarize the published literature from clinical trials of percutaneous TNS as a foundation of high-quality evidence for implantable devices targeting the tibial nerve.
胫神经是治疗膀胱过度活动症(OAB)及其相关症状(包括急迫性尿失禁(UUI))时既定的神经调节靶点。目前已有技术可通过经皮设备或植入式设备进行胫神经刺激(TNS)。经皮TNS的益处和安全性使其成为指南推荐的治疗方法。然而,患者的依从性受到每周门诊负担以及维持治疗需求的限制。此外,保险通常仅涵盖经皮TNS有限次数的终身就诊。这些因素以及其他因素促使了植入式TNS设备的开发、研究和应用。植入式TNS设备通过永久性植入设备提供与经皮TNS相同的神经刺激治疗作用机制,该设备可在家中进行刺激,而非在门诊进行治疗。此外,还具有动态和以患者为中心的刺激的额外潜力。关于TNS已发表了大量高质量证据,包括众多关于经皮TNS的随机对照试验,这些试验一致证明其疗效优于安慰剂,且与抗胆碱能药物的疗效相似。经皮TNS也比包括盆底肌肉训练在内的保守治疗效果更好。经皮和植入式方法通过相同的作用机制将神经刺激传递到同一目标神经。因此,经皮TNS随机试验的数据对植入式TNS设备具有参考价值。在本文发表时,至少有两种植入式TNS设备已获得美国食品药品监督管理局(FDA)的上市许可。本综述的目的是讨论TNS的作用机制,并总结经皮TNS临床试验已发表文献,作为针对胫神经的植入式设备高质量证据的基础。